Reimagining RNA medicine

Nov 15, 2024

Wave Life Sciences to Present at Jefferies London Healthcare Conference

Nov 12, 2024

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 04, 2024

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

Oct 30, 2024

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

Oct 16, 2024

Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Oct 16, 2024

Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

Oct 01, 2024

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Sep 30, 2024

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

Sep 25, 2024

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Sep 24, 2024

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants